A novel cholesterol dehydrogenase from Limosilactobacillus fermentum catalyzes the direct conversion of cholesterol to coprostanol

Urmila Netter[a], Vishakha Bisht[a], Amit Gaurav[a], Rekha Sharma[a], Avik Ghosh[a], Vinod Singh Bisht[b], Kiran Ambatipudi[b], Kapil Tahlan[c], Naveen K Navani[a*]

[a]Chemical Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology, Roorkee, Roorkee- 247667, Uttarakhand, India.

[b]Proteomics and Lipidomics Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology, Roorkee, Roorkee- 247667, Uttarakhand, India.

[c]Department of Biology, Memorial University of Newfoundland and Labrador, Livingston, St. John's, Newfoundland and Labrador, Canada.

*Address corresponding to: - Naveen K. Navani, Department of Biosciences and Bioengineering, Indian Institute of Technology, Roorkee, Roorkee- 247667, Uttarakhand, India. Telephone no- +91 1332285677

E-mail address: naveen.navani@bt.iitr.ac.in

Abstract

The gut microbiome harbors enzymes that can transform dietary cholesterol. Understanding this interaction can help tailor the diet to modulate host lipid homeostasis. Despite being exploited commercially as a probiotic, including a role in cholesterol reduction, the molecular mechanism of cholesterol transformation by lactobacilli still needs to be discovered. Herein, we elucidate the role of a novel microbial 3β-OH-Δ^{5-6}-cholesterol-5β-reductase from *Limosilactobacillus fermentum* NKN51, which directly converts cholesterol to coprostanol. Protein engineering provides insights into the catalytic mechanism of 5βChR. Phylogenetic studies indicate an abundance of 5βChR in gut commensal lactobacilli, which shares a common ancestor with plant 5β reductases. Meta-analysis of healthy participants microbiomes highlights the significance of the 5βChR homologs, and shotgun data analysis establishes an association between higher 5βChR abundance in diabetic patients (*p*-0.0213). The discovery and elucidation of the role of lactobacillus 5βChR in cholesterol metabolism may lead to designing functional foods tailored to ameliorate dyslipidemia.

Keywords: Cholesterol, $NADP^+$, *Limosilactobacillus fermentum* NKN51, Coprostanol MALDI-TOF.

Introduction

Since Eli Metchnikoff proposed the mutualistic connection between the gut, prolongation of life status, and gut inhabitants, lactobacilli have maintained a crucial status in human health and nutrition[1]. Lactobacilli help digest complex dietary substrates and protect the host from pathogens, thus touting them as commercially desirable health supplements and aids for food technology. Lactobacilli are given 'generally recognized as safe' (GRAS) status by the U.S. Food and Drug

Administration and a 'qualified presumption of safety' status from the European Food

Safety Authority[2]. Gut microbiota can perform the biotransformation of dietary fats and

lipids, including cholesterol. The cholesterol levels are modulated by gut microbiota

using mechanisms like bile salt hydrolysis, short-chain fatty acid-mediated cholesterol

uptake, and biotransformation of cholesterol[3]. However, elevated cholesterol levels

become the critical risk factor for cardiovascular diseases (CVDs) and atherosclerosis,

leading to heart failure, obesity, diabetes, fatty liver, and Alzheimer's disease[4-6]. The

hydroxysteroid dehydrogenase (HSDH) enzyme family has recently been shown to

contribute to gut cholesterol transformation[7]. The commensal microflora harbors

pyridine-dependent stereo- and regio-specific HSDHs, which can oxidize, reduce, and

epimerize the keto/hydroxyl groups at C-3, C-7, C-12, and C-20 of substrates[8,9].

HSHDs primarily include aldo-keto reductase (AKR), long/medium chain

dehydrogenase (MDR), and the Rossman fold containing short-chain dehydrogenase

(SDR), which catalyze conversion between enol and keto form of hydroxyl groups on

alcohol, carbohydrates, and xenobiotics[10-12]. SDRs are an extended family of over

2000 tyrosine-dependent oxidoreductases, with tyrosine as a catalytic residue[13]. The

SDRs contain conserved motifs spanning the Rossmann fold for $NADP^+/NAD^+$

cofactor binding and a catalytic tetrad comprising serine, tyrosine, lysine, and

asparagine amino acid residues[14,15]. Plant 5β reductases belong to the SDR class,

which contain Rossmann folds with a conserved catalytic motif NFYYYED[16]. The

function of 5β reductases in plants has undergone extensive investigations; however,

their role in the bacteria domain has been overlooked[17]. Only recently, the mechanism

of cholesterol metabolism has been deciphered in obligatory gut anaerobes

Eubacterium coprostanoligenes, Bacteroides thetaiotaomicron, and *Oscillibacter*

species[7,18,19]. The genome of *E. coprostanoligenes* encodes a cholesterol

dehydrogenase enzyme, 'Intestinal steroid metabolism A' (IsmA) that converts

cholesterol into cholestenone. Further, IsmA was found to convert coprostanone into

coprostanol[7]. However, information on the steps in transforming cholestenone into

coprostanone is lacking. On the other hand, *B. thetaiotaomicron* exhibits a unique

sulfotransferase activity that converts cholesterol into cholesterol sulfate[18]. Further,

Oscillibacter converts cholesterol to cholestenone, cholesterol glucoside, and

hydroxycholesterol[19]. Overall, coprostanol, cholesterol sulfate, cholesterol glucoside,

and hydroxycholesterol are excreted, thereby playing a role in cholesterol

homeostasis[7,18,19]. Even though the direct conversion of cholesterol to coprostanol in

the gut milieu was proposed as early as 1954[20], the mechanism of this transformation

has remained an enigma[3,21]. Interestingly, the lactobacilli have been implicated in the

modulation of host cholesterol levels for a long time, yet the mechanistic details of this

observation have also remained elusive[22-27].

Here, we report a novel cholesterol-specific microbial 5β reductase (5βChR) from

Limosilactobacillus fermentum NKN51, isolated from fermented Himalayan yak milk.

Our study presents mechanistic evidence of the direct conversion of cholesterol to

coprostanol by 5βChR through its 3β-OH-Δ^{5-6}-cholesterol-5β-reductase activity. We

also validate catalytic residues involved in cholesterol and $NADP^+$ binding to 5βChR.

Phylogenetic analysis identified 5βChR in lactobacilli, which shared a common

ancestor with plant 5β reductases. Metagenomic analysis of healthy individual

samples identified a high prevalence of 5βChR. Further, a comparative meta-analysis

of a cohort study indicated the correlation of 5βChR with diabetes. Our findings

addressed a primarily unexplored frontier of microbial cholesterol metabolism in *L.*

fermentum NKN51 by identifying a novel enzyme class from the SDR family,

establishing a path for unveiling the metabolic capabilities of one of the most popular

probiotic bacterium.

Results

L. fermentum **NKN51 shows** *in-vitro* **cholesterol dehydrogenase activity**

Lactobacilli are touted as probiotic strains for functional foods that lower host

cholesterol levels[28]. To understand the mechanism of cholesterol metabolism in

lactobacilli, we performed cholesterol depletion assays with a battery of lactobacillus

spp isolated from an ethnic fermented yak milk cheese (churppi) prepared by the

native population in the Western Indian Himalayas. *L. fermentum* NKN51 depleted the

maximum (~64%) cholesterol from the media compared to other strains

(Supplementary Fig. 1), and thus, we proceed with *L. fermentum* NKN51 for further

investigations. Since the cholesterol is known to be metabolized to coprostanol

through direct or indirect pathways[20], we checked the possible cholesterol metabolism

pathways in our bacterial strains by whole-cell lysate assays using thin-layer

chromatography (TLC) **(Supplementary Fig. 2)**. These results were further validated

by Matrix-assisted laser desorption/ionization- Time of flight (MALDI-TOF) analysis,

demonstrating that *L. fermentum* NKN51 strain converted cholesterol to coprostanol

(Fig. 1a-1e). We could not detect cholestenone or coprostanone in assays. These data

pointed towards the possibility that *L. fermentum* NKN51 might directly convert

cholesterol to coprostanol. These analytical assays also highlighted that the formation

of coprostanol by NKN51 was $NADP^+$-dependent but oxygen-independent

(Supplementary Fig. 3-4).

Biochemical characterization of putative microbial cholesterol dehydrogenase

To provide mechanistic insights into the putative cholesterol dehydrogenase enzyme for cholesterol to coprostanol transformation in *L. fermentum* NKN51, the recombinant protein was overexpressed and purified for analysis. The amino acid sequence of a known cholesterol SDR from *E. coprostanoligenes* HL ATCC51222[22] (WP_078769004.1) was used as a query against *L. fermentum* NKN51 draft genome, which selected a sequence with ~30% identity in NKN51. The putative cholesterol dehydrogenase was cloned, and the overexpressed protein of 29.5 kDa was purified by immobilized affinity chromatography (IMAC) **(Supplementary Fig. 5)**. The purified recombinant protein converted cholesterol to coprostanol using $NADP^+$ as a cofactor instead of NAD^+, validating our previous observation. **(Fig. 1f)**. Protein-cofactor-substrate isothermal titration calorimetry (ITC) studies corroborate that cholesterol dehydrogenase had an affinity for $NADP^+$ with K_d 6.88 µM, and the protein-$NADP^+$ complex displayed interaction for cholesterol with a K_d 4.66 µM **(Fig. 1g-1h)**. However, protein-$NADP^+$ did not show affinity towards cholestenone or coprostanone, substantiating that both of them are not the cognate substrates of the enzyme **(Supplementary Fig. 6)**. Further, the gel filtration chromatography depicted that the recombinant protein predominantly remains as a dimer in solution **(Supplementary Fig 7)**. The substrate specificity assay confirms that the enzyme can only perform saturation of the Δ5-6-oxo bond of the substrate with the OH group at the 3β position. Hence, the enzyme can specifically metabolize cholesterol to coprostanol **(Fig.1i)** **(Supplementary Fig. 8)**. These observations allude to the fact that the cholesterol dehydrogenase belongs to a novel class of SDR, i.e., 3β-OH- Δ^{5-6}- cholesterol-5β-reductase (5βChR). Kinetic studies on protein-substrate confirmed that 5βChR obeys the Michaelis- Menton equation with K_m 19.09 µM and V_{max} 15.35x10^{-6} µmol sec^{-1} $nmol^{-1}$ **(Supplementary Fig. 9)**. Furthermore, 5βChR transcript expression levels were ~1.5

137   fold higher when NKN51 was grown in the presence of cholesterol for 24h, verifying

138   5βChR genetic locus was induced upon cholesterol-supplementation (p-0.0022) in the

139   native host **(Fig. 1j)**.

Figure 1: *L. fermentum* NKN51 harbors a cholesterol dehydrogenase that can convert cholesterol to coprostanol

(a-d). Matrix-assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) chromatograms show the peaks of sterol standards, cholesterol, cholestenone, coprostanone, and coprostanol, which are represented by their respective mass-to-charge (m/z) ratios. **(e).** *L. fermentum* NKN51 enzymatic activity is assessed by its whole-cell lysate (WCL) assay in the presence of cholesterol (100 µM) and NADP$^+$ (100 µM) for 12 h under anaerobic conditions. The reaction mixture is evaluated by MALDI-TOF, illustrating the presence of coprostanol with an m/z of 371.701. **(f).** The MALDI-TOF spectra graph shows the result of an *in-vitro* biochemical assay of purified cholesterol-5β-reductase (5βChR) incubated with NADP$^+$ (100 µM) and cholesterol (100 µM) in the 20 mM Tris-cl (pH-7.8) for 12 h. It depicts the peak of coprostanol (m/z-371) as a product of cholesterol metabolism. **(g).** Isothermal Titration Calorimetry (ITC) data displaying binding affinity of the 5βChR (20 µM) for NADP$^+$ (1 mM). **(h).** The titration curve provides the interaction between the 5βChR + NADP$^+$ complex and cholesterol (500 µM), where DP stands for differential power, and ΔH represents the enthalpies (normalized with the control). **(i).** The bar graph indicates the conversion of cholesterol to coprostanol (grey block) by 5βChR under the same conditions. The other structurally similar compounds are not metabolized into their respective metabolites. Abbreviations: PG stands for pregnenolone, LA-lithocholic acid, CA-cholic acid, and HC-hydrocortisone. Spectra analysis of this substrate specificity assay is given in Supplementary Figure 8. **(j).** The transcript levels of 5βChR in a cholesterol-rich medium compared to a medium without cholesterol at 24 h under anaerobic conditions show ~1.5-fold change. In the graph, each point represents a biological replicate, with the centre bar representing the mean and the error bars representing

166 the standard deviation. ** denotes the *p* value- 0.0022 calculated by the Mann-Whitney

167 test.

Structural analysis of cholesterol dehydrogenase-5βChR

The 5βChR structure was predicted using AlphaFold2 with high confidence (>90%),

high pre-residue confidence score (>90%), and a low domain position confidence.

These scores highlight the high local confidence around each amino acid and

position/orientation confidence between individual domains. The 5βChR tertiary

structure depicts conserved motifs of the SDR superfamily, including the N-terminus

dinucleotide binding Rossmann fold consisting of seven central β-strands flanked by

six α-helices and a catalytic tetrad (NSYK) **(Fig 2a-2b)**. Molecular docking indicates

that cholesterol was bound to the C-terminus of the protein where cholesterol steroid

ring-1 interacts with 5βChR through hydrophobic forces by methionine (Met189) and

phenylalanine (Phe190). An electrostatic bond was observed between 5βChR

threonine (Thr187) and the hydroxyl group of cholesterol. Protein-cholesterol

interaction was also accompanied by hydrophobic interactions with proline (Pro182 &

Pro184), phenylalanine (Phe190, Phe198 & Phe239), and glycine (Gly183). Hence,

the positioning of the sterol in 5βChR was complemented by Van der Waals repulsion

energies. $NADP^+$ was bound to the N-terminus of the 5βChR via the conserved

glycine-rich (Gly 8, 9, 12, and 14) motif (GXXGXXG) of the SDR enzyme family.

Tyrosine (Tyr152), lysine (Lys156), serine (Ser11), and threonine (Thr10 and Thr187)

residues of the protein contributed to a total of eight polar interactions with $NADP^+$.

Further, Tyr152 and Lys156 amino acid residues of 5βChR were likely to interact with

the nicotinamide oxygen (O=C-NH). The hydroxyl chain of Ser11 and Thr10 had an

affinity with the pyrophosphate group's oxygen and phosphate group of ribose,

respectively. Van der Waals forces were involved between NADP$^+$ and Ala32, Arg33,

Gly89, Ile89, Ser139, Asp146, Met149, Ser11, Ile90, and Ala9 of 5βChR **(Fig. 2c)**.

Structural homologs of 5βChR were retrieved from DALI server, which was identified

as SDR reductase (PDB ID: 5X8H), Sorbitol dehydrogenase (PDB ID: 4NPC), and

Putative oxidoreductase RV2002 (PDB ID: 1NFR). The superimposed images of these

enzymes onto 5βChR displayed root square mean value (r.m.s) deviation of 1.3, 1.3,

and 1.2 Å, respectively. These proteins share a topological arrangement with 5βChR.

However, 5βChR had an extended C-terminus, which is not present in either of the

homologs. These observations confirm the previous sequence alignment-based

prediction that the cholesterol dehydrogenase, 5βChR, belongs to an enzyme of the

SDR category **(Supplementary Fig. 10)**.

Identification of catalytic residues for NADP$^+$ and cholesterol binding in 5βChR

Using site-directed mutagenesis, we elucidated the role of catalytic tetrad (NSYK) and

other conserved residues of 5βChR. Since the C-terminus of SDRs was reported for

substrate binding[10], we mutated the C-terminus of the protein to investigate its role in

cholesterol binding **(Supplementary Fig. 11)**. The TLC and MALDI experiments with

the purified mutants revealed that the cholesterol transformation ability of serine

(Ser139A), tyrosine (Tyr152A), threonine (Thr187A), methionine (Met189A), and

phenylalanine (Phe190A) 5βChR mutants was abrogated **(Supplementary Fig. 12-**

13). Further, ITC data revealed that S139A and Y152A mutants lost the NADP$^+$ binding

ability **(Supplementary Fig. 14)** yet retained the binding ability for cholesterol with a

K_d, 24.8 µM and 4.44 µM, respectively **(Fig 2d-2e).** On the other hand, T187A, M189A,

and F190A retained the NADP$^+$ binding ability (K_d 8.77 µM, 7.49 µM, and 5.2 µM

respectively) **(Fig 2f-2h) (Supplementary Fig. 14)** and lost the ability to bind to

cholesterol, thus revealing that indeed the C-terminus of the 5βChR is important for

the substrate interaction. Other mutations, like N136A, K156A, H131A, Y170A, E172A,

and T187A, did not affect the ability for conversion of cholesterol to coprostanol, thus

indicating their non-significant role in the enzyme activity **(Supplementary Fig 13)**.

We compared the NADP$^+$-binding pocket of 5βChR with the 5β-progesterone

reductase (5β-POR) complexed with NADP$^+$ (PDB: 2V6G)[16]. The Rossmann fold was

responsible for NADP$^+$ binding in plant and microbial 5β reductase **(Fig. 2i-2j)**.

However, the lysine residue of a conserved catalytic tetrad of SDRs does not interact

with the O-2' and O-3' of nicotinamide ribose in both cases[14,29]. In the 5β-POR, two

arginine residues (Arg63 & Arg64), and in 5βChR a serine (Ser139) and tyrosine

(Tyr152) were responsible for cofactor binding **(Fig. 2i-2j)**. This reinforces that 5βChR

retains the structural features of both SDRs and 5β-POR. The circular dichroism

spectra analysis of wild-type and mutant 5βChR enzymes did not reveal any change

in the protein structure, indicating that the observations about cofactor and substrate

binding were not due to perturbations in the secondary structure of the 5βChR

enzymes. The observed changes were likely due to the ability of substrate and cofactor

binding ascribed to the amino acids mutated. **(Supplementary Fig. 15)**.

Figure 2: Structure and mutation analysis of 5βChR for ligand binding and comparison study with the nicotinamide binding pocket of plant 5β reductase.

(a). Apo structure of 5βChR deciphered by Alphafold2 and visualized by PyMOL. The structure exhibits the SDR-characteristic N-terminus Rossmann fold consisting of seven central β-strands (β3- β2- β1- β4- β5- β6- β7) flanked by six α-helices. **(b).** The surface representation of 5βChR shows the active binding pocket of cholesterol and NADP⁺ (blue). **(c).** The molecular docking results of 5βChR-NADP⁺-cholesterol depict

the interacting amino acids. The Cofactor (NADP⁺) binding pocket highlights the ionic

interaction (red) (indicated by dashed lines). The amino acids involved in hydrogen

bonding are Thr10, Ser11, and Tyr152, while Lys156, Ala32, Arg33, Gly89, Ile89,

Ser139, Asp146, Met149, Ser11, Ile90, and Ala9 showcase involvement in van der

Waals bonds (green). Protein-substrate (5βChR-cholesterol) complex shows

hydrophilic interaction with Thr187, whereas the hydrophobic forces are present

between Pro182, Pro184, Met189, Phe190, Phe198, and Phe238. **(d-h).** The

normalized enthalpy curves represent the interaction profile of 5βChR mutants with

their ligands. S139A (d) and Y152A (e) mutants have an affinity for cholesterol and lost

binding for NADP⁺ (Supplementary Figure 13). T187A, M189A, and F190A mutants

do not bind to cholesterol (Supplementary Figure 13). In contrast, they retained affinity

for NADP⁺ (f-h). **(i-j).** The comparison study of the active site of 5βChR and plant 5β

reductase (5β-POR) with their respective substrates. The stereo view of 5βChR

complexed with NADP⁺ is mediated by tyrosine (Tyr152) and serine (Ser139) of the

conserved tetrad. In 5β-POR - two arginine residues (Arg63 & Arg64) stabilise NADP⁺

interaction.   5β-POR has two Rossmann folds (glycine residues) (GXXGXXG),

whereas 5βChR harbors a single N-terminus fold, contributing to NADP⁺ binding.

Distribution and abundance analysis of 5βChR

Since 5βChR turned out to be a novel class of enzyme discovered in bacteria, we

focused on assessing the diversity and abundance within Lactobacillaceae and overall

in eubacteria. A local database of 256 lactobacilli was screened to assess the

prevalence of 5βChR in their genomes **(Supplementary File. 1)**. A maximum

likelihood method confirmed the presence of 5βChR sequence in 84 lactobacilli

genomes, which were further divided into six major clades. Most of these

representatives (*Lactiplantibacillus plantarum, Limosilactobacillus mucosae,*

Levilactobacillus parabrevis, *Latilactobacillus sakei*, *Latilactobacillus curvatus*,

Ligilactobacillus salivarius, and *Levilactobacillus brevis*) were associated with a

healthy commensal gut community[30,31] **(Fig. 3a)**. We traced the evolutionary

relationship of microbial 5βChR with plant 5β reductases using the human homolog

as an outgroup **(Supplementary File. 1)**. The phylogeny analysis revealed that

human, plant, and microbial 5β reductases originated from a common ancient

ancestor. **(Fig. 3b)**. With an aim to assess the distribution of 5βChR in different

microbial taxa, we retrieved 5000 5βChR homologs and interpreted the data using

Cytoscape. 5βChR homologs were grouped into 33, 138, and 269 clusters with

threshold values for sequence identity (e-value) of 10^{-60}, 10^{-70}, and 10^{-80}, respectively

(Supplementary Fig. 16) (Supplementary File. 1). Finally, a threshold value of 10^{-80}

was chosen to map the 5βChR homologs to ensure similar functional and structural

aspects, which led to the grouping of proteins into 269 distinct clusters **(Fig. 4a).** The

phylum-level taxonomic classification of respective clusters were taken into

consideration to assess the evolutionary origin these sequences. Cluster 1 had 934

homologs belonging to Pseudomonadota (Proteobacteria) (87.04%), Actinomycetota

(Actinobacteria) (11.56%), and Planctomycetota (0.74%). Cluster 2 had 26 phyla,

predominately from Chloroflexota (21.9%), Cyanobacteria (12.44%), Acidobacteriota

(10.18%), Bacillota (Firmicutes) (8.59%), Actinomycetota (6.7%), Candidatus

omnitrophota (5.4%) and an uncharacterized class (4.29%). Cluster 3 was the most

diversified SSN cluster, accounting for 36 phyla, out of which Bacillota (54.2%) was

the most prevalent phylum, comprising half of the homologs. Interestingly, Bacillota

was also a dominant phylum in 5, 6, 8, 9, 10, 11, 16, 52, 56, 83, 128, 139 and 249

clusters **(Fig. 4b) (Supplementary Fig. 17).** Pseudomondata was present in clusters

4, 7, 12, and 15, while cluster 13 was abundant with Bacteroidata. These observations

highlight the presence of the 5βChR in *Clostridia, Eubacteria, Oscillopsia,*

Peptostreptococcus, Fusobacteria Bifidobacteria, and Lactobacillus **(Fig. 4b-4c)**

(Supplementary Fig. 17). The SSN analysis indicates that inhabiting different niches

belonging to different phyla harbor 5βChR homologs, possibly providing some benefit

to their respective hosts **(Fig. 4c)**.

Figure 3: **Mapping the prevalence of 5βChR within (a) lactobacilli and (b) plants by phylogenetic profiling.**

(a). The cladogram of 5βChR protein across 256 lactobacilli depicts its abundance in 84 strains. This study used the PROTCATWAG model in RAxML and rooted using the branch leading to *Lacticaseibacillus songhuajiangensis* and *Escherichia coli* as the outgroups. **(b).** The evolution analysis of 5βChR homologs in plants (~100) is acquired from UniProt in RAxML using the PROTCATWAG model with human 5β reductase as an outgroup. 5βChR and plant 5β reductase evolved from a common ancestor. A pink circle indicates a bootstrap value of more than 70.

Meta-analysis of 5βChR abundance in microbiomes of healthy microbiomes

With an aim to assess the importance of aforementioned 5βChR clusters, we assessed the data through ShortBRED consisting of protein class in 380 high-quality healthy human metagenome sequences (from the human microbiome project), covering samples from stool, buccal mucosa, supragingival plaque, tongue dorsum, anterior nares, and vaginal fornix **(Supplementary File. 1)**. Through EFI-Computationally-Guided Functional Profiling (EFI-CGFP) tool we identified 20 clusters of 5βChR homologs in Human Microbiome Project data **(Fig. 5a)**. Clusters 3, 9, and 11 were abundant in the oral microbiome (supragingival plaque, buccal cavity, and tongue dorsum), whereas 2, 3, 6, 9, 11, 52, 83, 104, 119, 122, 128, 140, 156, 172, 185, and 24 were dominant clusters in the fecal samples, indicating the presence of 5βChR homologs in anaerobes. Bacillota-dominated clusters, 16 and 139, showed higher distribution in the posterior fornix (vaginal microbiome) and anterior nares **(Fig. 5b) (Supplementary Fig. 18)**. The varying abundance of 5βChR unveiled the enzyme's ecological diversity in humans and reinforced its potential contribution to

319   maintaining human physiological homeostasis. No clusters were dominated by phyla-

320   Acidobacteria, Nitrospirota, and Chloroflexota, likely indicating their functional

321   insignificance to humans.

Figure 4: Network maps illustrating the abundance and distribution of the 5βChR gene family across the different microbes.

(a). Microbial origin 5βChR protein homologs are retrieved from UniProt for sequence similarity network (SSN) analysis. These networks are visualized by the Enzyme Function Initiative-Enzyme Similarity Tool (EFI-EST) with threshold values of 10^{-80}. The proteins are divided into 269 clusters based on sequence identity, structural similarities, and functional profile of 5βChR proteins, highlighting their presence in various microbes. **(b)** The graphs depict the taxonomy of microbial 5βChR homologs from the selected clusters, which are prevalent in human microbiome data. The representative sequences of clusters belong to different bacteria belonging to diverse phyla and families.

5βChR has an inverse association with diabetes

Diabetes can induce changes in lipid levels, leading to diabetic dyslipidemia, which escalates risk factors for CVDs[32-34]. We investigated the relationship between 5βChR and diabetes using Chinese type 2 diabetes shotgun data (PRJNA3855128). The two independent metagenomic cohorts were diabetic individuals (n=10) and healthy controls (n=10). The interpretation of data validated that 5βChR exhibits a significantly higher prevalence in healthy individuals than those with diabetes (p-0.0213) **(Fig. 5c)**. This corroborates the inverse relationship between 5βChR and diabetes within this cohort study, thereby indicating that 5βChR expression may play a role to lower the chance of diabetic dyslipidemia.

 AN- Anterior nares, BM- Buccal mucosa, SP- Supragingival plaque, TD- Tongue dorsum, S- Stool, and PF- Posterior fornix

345 Figure 5: Meta-analysis depicts the abundance of 5βChR homologs in healthy

346 microbiomes and comparative analysis in a human diabetic cohort study.

(a). The heat map depicts the prevalence of 5βChR homologs in the human metagenomic data of 380 healthy individuals. Analysis validates the presence of 20 clusters in the participants' metagenome data. **(b).** The box-plot graphs highlight the presence of 5βChR homologs in various body sites. Clusters 3, 9, 11, and 56 dominate the oral microbiome (supragingival plaque, buccal cavity, and tongue dorsum) and stool samples. Cluster 16 is predominant in vaginal samples. The enzymes from other clusters 139 showed higher distribution in anterior nares samples of human microbiomes. Further, clusters 83 and 249 are abundant in stool samples, indicating their abundance in the gut. **(c).** 5βChR has a lower abundance among diabetic patients than healthy individuals in the shotgun metagenomic data of a Chinese type 2 diabetes cohort study. Individuals with 5βChR high copy number are predominantly reported as healthy. The points in the graph represent the number of individuals in each category. *p value- 0.0213 is determined by the Mann-Whitney test.

Discussion

The gastrointestinal tract is a site for cholesterol metabolism and regulation of blood cholesterol levels. Although cholesterol metabolism by lactobacilli has been known for almost 50 years, the exact mechanism has remained elusive[3]. Recently, three independent studies have reported the mechanism of cholesterol metabolism by different bacterial gut residents. Still, the role of lactobacilli has not been addressed in either of the reports[7,18,19]. Here, we provide the first mechanistic evidence for the direct conversion of cholesterol to coprostanol by lactobacilli. We demonstrate that *L. fermentum* NKN51 harbors 3β-OH-Δ^{5-6}-cholesterol-5β-reductase(5βChR), representing a novel class within the SDR family that catalysis the transformation of cholesterol to coprostanol **(Fig. 6)**. The 5βChR sequence exhibits the characteristic

features of SDRs. Unlike typical microbial SDRs, 5βChR remains primarily a dimeric

protein that can catalysis direct coprostanol formation by reducing cholesterol's 5, 6

double bond. Hence, the distinctive features of 5βChR ascribed it to a newly identified

class within microbial SDRs. The structural and functional analysis of 5βChR

deciphered the molecular basis of the catalysis of cholesterol to coprostanol.

Molecular docking-inspired observations of the cofactor and substrate with the wild

type and mutant 5βChR identified the critical residues for $NADP^+$ binding and revealed

the novel residues important for cholesterol binding to the protein. Evolutionary

analysis of plant and microbial 5βChR enzymes suggests both are paraphyletic

groups. The phylogeny data confirms the presence of 5βChR in gut lactobacilli,

signifying its possible importance in human physiology. The shotgun data analysis

confirms low levels of 5βChR transcripts in diabetic patients. Thus, 5βChR may exert

an influence to lower the chance of premature coronary heart disease and stroke in

diabetic dyslipidemia conditions[35]. Metagenomic mining reveals that the

representatives of the 5βChR are distributed across various bacterial genera, with a

predominant presence in firmicutes. Our findings suggest that 5βChR homologs are

also acquired by uncharacterized bacterial classes, which may be explored further.

The prevalence of 5βChR in microbiomes of healthy individuals suggests its

paramount multifaceted functional aspects in lipid homeostasis. At the forefront of our

work, we unfolded the cholesterol transformation through its direct conversion to

coprostanol by a potential probiotic, *L. fermentum*. A similar strategy can unravel the

intricate interplay between gut microbe-mediated metabolism of diverse biological

molecules that influence physiological homeostasis or initiate complex diseases. By

delving into this mechanistic biology, we pave the way for developing next-generation

probiotics that can be explored for the formulation of functional foods and may also

synergize with host-targeted lipid-lowering medications, offering a promising

intervention for combating hypercholesterolemia.

Figure 6: A comprehensive representation of microbially mediated cholesterol

transformation in the human gut.

Various gut microbes transform cholesterol in the gut via direct and indirect pathways.

(a). A cholesterol dehydrogenase (ismA) of *Eubacterium coprostanoligenes* is reported

to catalyze the first and last step of the indirect pathway of cholesterol metabolism.

(b). The gut cholesterol is also converted to cholesterol-sulphate with the help of a

cholesterol sulfotransferase encoded by *Bacteroidetes thetaiotaomicron.* **(c).** A group

of enzymes, cholesterol-α-glucosyltransferase, and translocator protein expressed by

Oscillibacter species transformed cholesterol into cholesterolglucoside and

hydroxycholesterol while **(d).** a comprehensive study on 5βChR *Limosilactobacillus*

fermentum NKN51 can directly convert cholesterol to coprostanol by a cholesterol-5β-

reductase.

Online Methods

In-vitro **cholesterol reduction assay**

Limosilactobacillus fermentum NKN51[36], *Lacticaseibacillus casei* NKN344, and

Lacticaseibacillus casei NKN347 were fermented food isolates from our lab. For the

cholesterol estimation assay, the bacterial strains were inoculated with cholesterol

(Sigma Aldrich, USA) (100 µg/ml) dissolved in methanol (Merck, USA) further, added

to sterile anaerobic Man, Rogosa, and Sharpe (MRS) media (Difco Laboratories, USA)

supplemented with Sodium thioglycolate (STG) (0.1%) (Tokyo Chemical Industry,

China) and incubated at 37°C for 24 h. After incubation, the samples were centrifuged

at 13,000 rpm for 5 min. The supernatant was subjected to a cholesterol estimation

assay using the Rudel and Morris method[37]. This was done in triplicates, and then

average values were plotted. *L. fermentum* NKN51 culture of 12 h was pelleted by

centrifugation at 4500 rpm for 20 min at 4°C and resuspended in phosphate buffer

saline (PBS) (1x) (Sigma Aldrich, USA) and lysed with Branson probe sonicator 102C

(CE) (Thermo Fisher Scientific, USA). Disrupted cells were centrifuged at 13,000 rpm

for 30 min at 4°C, and then the supernatant was collected separately. Cholesterol (100

µM) dissolved in methanol and $NADP^+$ (100 µM) (Sigma Aldrich, USA) were added to

the 500 µL supernatant and incubated at 37°C for 12 h. As described above, sterols

were extracted from these reaction mixtures and analyzed by TLC (explained later).

Reaction products were also checked with MALDI-TOF (details are in the MALDI-TOF

instrument section).

Cloning of putative cholesterol dehydrogenase gene

The genomic DNA of *L. fermentum* NKN51 was isolated using the HiPurA® Bacterial

Genomic DNA Purification Kit (Himedia, India). The gene encoding 5βChR was

amplified using Phusion High Fidelity DNA polymerase (Thermo Fisher Scientific,

USA) with the primers listed in **Supplementary File. 1**. Further, the PCR product and

pET28(a) were double digested with NdeI (Thermo Fisher Scientific, USA) and XhoI

(Thermo Fisher Scientific, USA). The digested products were ligated using T4 DNA

ligase (Thermo Fisher Scientific, USA) and transformed into chemically competent

cells of *E. coli*. Transformants were checked with double digestion of the construct,

followed by sequencing.

Site-directed mutagenesis of putative Cholesterol dehydrogenase gene

443   5βChR mutants were constructed with the Q5® Site-Directed Mutagenesis Kit (New

444 England Biolabs, USA). Primers containing the desired mutation were designed with

445 the NEBase Changer webpage tool (https://nebasechanger.neb.com/). The primers

446 were mentioned in the **Supplementary file. 1**, and transformants were confirmed by

447 sequencing.

Overexpression and Purification of N-His Terminal Tagged WT and mutants
5βChR proteins

Plasmid clones containing 5βChR were transformed into ultra-competent BL21AI

(Arabinose   Induction)   (Thermo   Fisher   Scientific,   USA)   cells   for   protein

overexpression. 5βChR protein (29.5 kDa) overexpression was optimized with IPTG

(0.05 mM) (Tokyo Chemical Industry, China) and Arabinose (0.2%) (Himedia, India).

For protein purification, the cells were grown in Luria-Bertani broth (Difco Laboratories,

USA) supplemented with kanamycin (50 µg/ml) (Sigma Aldrich, USA) overnight at

37°C with shaking at 180 rpm. The secondary culture was inoculated with a primary

culture of WT and mutant 5βChR (1%), incubated at 37°C with shaking at 180 rpm

until optical density (OD_{600}) reached ~0.8. The bacterial cultures were induced with

IPTG (0.05 mM) and 0.2% Arabinose (0.2%) and incubated at 18°C with shaking at

180 rpm for 18 h. Cells were harvested at 4500 rpm for 20 min at 4°C and resuspended

into 20mL buffer A (50 mM Tris-Cl, 500 mM NaCl 5% glycerol) (pH-7.8). The

resuspended cells were lysed with a Branson probe sonicator 102C (CE) and then

centrifuged at 4500 rpm for 30 min and 4°C. The clarified supernatant was loaded into

the buffer A saturated His Trap column of AKTA Pure-50L (GE Healthcare). Purified

protein fractions were eluted with Buffer B (50 mM Tris-Cl, 500 mM NaCl, 500 mM

Imidazole 5% glycerol) (pH-7.8) and analyzed using SDS-PAGE. Further, the protein

was dialyzed in dialysis buffer (20 mM Tris-Cl, 300 mM NaCl 5% glycerol) with a 10

kDa membrane (Pall Corporation Centrifugal Devices, USA) for 8 h intervals. The

protein was checked on SDS-PAGE and stored in aliquots at -80°C. Purified protein

fractions were analyzed for protein-substrate binding and enzymology assays using a

method previously explained.

Instrumentation conditions of MALDI-TOF for measurement of sterols

A Bruker ultrafleXtrem mass spectrometer equipped with a smart-beam-II laser was

used to identify the cholesterol and related metabolites. A lipid sample mixed with 2,5-

Dihydroxybenzoic acid (DHB) matrix (1:1) and 1 µl mixture of sample and matrix were

spotted on the MTP AnchorChip target plate (Bruker Daltonics GmbH). Nd: YAG laser

(355 nm/2000Hz/500 shots/50-60% intensity) was used for the ionization of the

sample, and mass spectra were acquired in the positive reflectron mode at 100-800

Da mass range using FLEXCONTROL 3.0, (Bruker). Spectra were processed by

centroid peak picking, and spectrum analysis was done in LEXANALYSIS 3.0

(Bruker).

482 qPCR of 5βChR transcript

The chloroform-phenol (VWR, USA) extraction method was used for total RNA

purification from triplicate *L. fermentum* NKN51 cell pellets from cultures grown with or

without cholesterol for 24 h. DNase-treated RNA samples were used to prepare cDNA

using PrimeScript 1st strand cDNA Synthesis Kit (Takara, Japan). 5βChR transcript

was quantified by real-time PCR with PowerTrack SYBR Green Master Mix (Applied

Biosystems, USA). It was normalized with 16S rRNA gene expressions. Primers used

in the analysis are listed in the **Supplementary File. 1**.

490 Thin Layer Chromatography of sterols

The reaction set-up contains an enzyme (10 nm), $NADP^+$ (100 μM), and substrate

(100 μM) (cholesterol, cholestenone, and coprostanone) in the dialysis buffer,

incubated at 37°C for 12 h. These reaction mixtures were used for sterol extraction

using the previously explained method and analyzed on TLC. The organic layer was

evaporated, resuspended in 10 μl of methanol, and spotted on a pre-treated TLC plate

(silica gel IB2-F flexible 20 x 20 cm) with methanol at 100°C for 30 min. The sterols

were separated with mobile phase (Benzene: Chloroform) (90:10) (Merk, USA). The

Plate was visualized after being treated with 15% sulphuric acid in methanol and

incubated at 110°C for 10 min.

Gel Filtration chromatography of 5βChR

5βChR gel filtration chromatography (column: Hiload™ 16/600 Superdex™ 200pg) was performed on an AKTA pure-50L chromatography system (GE Healthcare) at 4°C. The concentrated, purified protein (10 mg/mL) was loaded onto the analytical column equilibrated with Tris-Cl (20 mM) and NaCl buffer (200 mM) at pH 7.8 and eluted at a flow rate of 1ml/min. A protein standard consisting of thyroglobulin bovine, γ-globulins, Ovalbumin, Ribonuclease A type I, and p-aminobenzoic acid (pABA) (Merck, India) was used to determine the native molecular mass of 5βChR.

Enzyme kinetic assay

The enzyme activity of the purified protein was measured spectrophotometrically by monitoring $NADP^+$ levels at 340nm. The standard reaction mixture comprised sodium acetate trihydrate buffer (20 mM) (pH 7.8), $NADP^+$ (100 µM), enzyme (20 nm), and substrate concentration varied from 10 to 300 µM. GraphPad Prism was used to plot the data using the Michaelis-Menton saturation curve and Lineweaver-Burk plots to calculate kinetic parameters.

Substrate-specificity assay

Cholic acid, lithocholic acid, pregnenolone, hydrocortisone (100 µM) (Tokyo Chemical Industry, China), or different substrate analogs of cholesterol were separately added with the same cholesterol concentration as a control. The reaction was incubated at 37°C for 12 h after the sterols were extracted and run on the MALDI to check the enzyme activity 5βChR for structure analogs of cholesterol.

Circular Dichroism spectroscopy of WT 5βChR and mutants.

CD spectroscopy of 5βChR (WT) or mutants was conducted using a J-815 CD

spectropolarimeter (Jasco, Tokyo, Japan). The samples of the protein (20 μM) were

prepared in KH_2PO_4 buffer (10 mM) (pH 7.8). For the CD scan, a quartz cell with a 0.1

cm was used, and scans were carried out at 25°C from 190 to 260 nm at a speed of

50 nm/min with wavelength pitch with three accumulation data. Data were analyzed

using GraphPad Prism.

Isothermal Titration Calorimetry assay for binding analysis

ITC analysis was performed using a MicroCal PEAQ-ITC (Malvern Panalytical, United

Kingdom) with 300 cell volumes. $NADP^+$ cofactor was dissolved in the dialysis buffer,

and the substrate was dissolved in methanol. Purified 5βChR (20 μM) was injected

with 18-successive 2 μl aliquots of $NADP^+$ (1 mM) at 150 s intervals. Further, protein-

$NADP^+$ was injected similarly with a substrate (500 μM). The data were fitted to a

nonlinear regression model using a single binding site with the MicroCal origin

software. The thermodynamic parameters were calculated using the Gibbs free energy

equation ($\Delta G = \Delta H - T\Delta S$ and $\Delta G = -RT\ln(K_a)$).

5βChR structure determination

5βChR structural modelling was done using ColabFold (v.1.5.5) implementation of

Alphafold (https://github.com/sokrypton/ColabFold)[38,39]. The multiple sequence

alignment was done using the MMseq2 algorithm[40]. The models were ranked through

the pTM score, and the highest-scoring model was used for analysis. PyMOL[41] (v2.5.7

Schrödinger, LLC) was used for protein visualization and structural analysis of 5βChR.

DALI server[42] was used for structural similarity search.

Molecular docking of multiple ligands docking with 5βChR

The three-dimensional structure of 5βChR was predicted using ColabFold (v.1.5.5),

which uses MMseqs2 along with AlphaFold2 in its background[38,39]. The potential

ligands of 5βChR-NADP$^+$-cholesterol datasets were downloaded from the ZINC drug

database in SD format (https://zinc.docking.org/). AutoDockTools-1.5.7 was used to

convert the 5βChR PDB files and ligand structures into PDBQT format[43]. Autodock

Vina (v.1.2.3) performed molecular docking with multiple ligands[44]. The protein-ligand

interactions were computed and were subsequently visualized by PyMOL[41] (v2.5.7

Schrödinger, LLC).

553　Phylogenetic analysis of 5βChR within lactobacilli and plants

The prevalence of 5βChR was examined by creating a protein-based custom-made

database for available lactobacilli from RefSeq using BLAST (v2.15.0)

(Supplementary File. 1). 5βChR was used as a query search in the database, and

the homologous proteins were retrieved for evolutionary studies. To trace the ancestral

relationship of 5βChR in plants, 100 related sequences were taken out from UniProt[45]

(https://www.uniprot.org/). MUSCLE (v3.8.31)[46] aligned all respective sequences, and

phylogenetic analysis was done using RAxML (v8) by the maximum likelihood Protcat

blossom62 model[47].

562　5βChR sequence similarity network data analysis

563　For 5βChR sequence similarity network (SSN)[48] analysis, its amino acid sequence

564　was used as a query in the UniProt database using BLASTp with a series of cutoff e-

565　values- 10^{-60}, 10^{-70}, and 10^{-8} and protein identity values of >50%, >60% and >70%

566　respectively. The EFI-EST tool was used to construct the protein SSNs of these

567　sequences with various e-values and visualized by Cytoscape 3.3[49].

Determination of 5βChR abundance using healthy human metagenome data

5βChR abundance was checked in the HMP[50,51] as previously described using the ShortBRED[52,53] **(Supplementary File. 1)**. This was done using the EFI-chemically guided functional profiling (EFI-CGFP) platform[54-56]. Using UniProt, 5βChR sequence representatives were filtered at 80% amino acid similarity thresholds to identify non-redundant peptide markers. ShortBRED-quantify was used with default parameters to quantify the marker abundances in the 380 metagenomic database. The relative abundance is based on reads per kilobase million (RPKM) values calculated and converted into 'copies per microbial genome' as explained earlier[56,57].

Abundance analysis of 5βChR gene in human gut metagenomes under disease conditions

The shotgun metagenomic sequencing datasets of the human gut microbiomes describing diabetes were downloaded from the Sequence Read Archive of the NCBI (https://www.ncbi.nlm.nih.gov/sra). The dataset was divided into healthy and diseased based on the metadata provided with the original data. Read quality was checked using FastQC (v0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) followed by MultiQC (v1.11)[58]. Only reads with a phread score higher than 30 were included in the study. The high-quality sequencing reads were assembled using MEGAHIT (v1.2.9) with a minimum contig length of 500 bp[59]. Assembled sequences were matched to the nucleotide sequence of 5βChR using DIAMOND (v2.0.15.1531) with the following parameters: e-value – 0.00001, query coverage 30, percent identity 30[60].

Data availability

The data is provided in the manuscript as supplementary information.

Code availability

No custom-made code was used in this study.

References

1. Underhill, D., Gordon, S., Imhof, B. *et al.* Élie Metchnikoff (1845–1916): celebrating 100 years of cellular immunology and beyond. *Nat Rev Immunol* **16**, 651–656 (2016).

2. Dempsey E and Corr SC Lactobacillus spp. for Gastrointestinal Health: Current and Future Perspectives. *Front. Immunol*. **13**:840245 (2022). doi:10.3389/fimmu.2022.840245

3. Jia, B., Zou, Y., Han, X., Bae, J. W., & Jeon, C. O. Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease. *Trends Microbiol.*, **31(1)**, 76–91 (2023).

4. Puglielli, L., Tanzi, R. & Kovacs, D. Alzheimer's disease: the cholesterol connection. *Nat Neurosci* **6**, 345–351 (2003).

5. Berger, S., Raman, G., Vishwanathan, R., Jacques, P. F., & Johnson, E. J. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. *The Am. J. Clin. Nutr.*, **102(2)**, 276–294 (2015).

6. Song, Y., Liu, J., Zhao, K., Gao, L., & Zhao, J. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. *Cell Metab.*, **33(10)**, 1911–1925 (2021).

7. Kenny, D. J., Plichta, D. R., Shungin, D., Koppel, N., Hall, A. B., Fu, B., Vasan, R. S., Shaw, S. Y., Vlamakis, H., Balskus, E. P., & Xavier, R. J. Cholesterol

Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level. *Cell host & microbe*, **28(2)**, 245–257.e6 (2020).

8. Mythen SMDevendran SMéndez-García C, Cann I, Ridlon JM. Targeted Synthesis and Characterization of a Gene Cluster Encoding NAD(P)H-Dependent 3α-, 3β-, and 12α-Hydroxysteroid Dehydrogenases from Eggerthella CAG:298, a Gut Metagenomic Sequence. Appl Environ Microbiol., **84** : e02475-17 (2018).

9. Doden, H. L., Pollet, R. M., Mythen, S. M., Wawrzak, Z., Devendran, S., Cann, I., Koropatkin, N. M., & Ridlon, J. M. Structural and biochemical characterization of 20β-hydroxysteroid dehydrogenase from Bifidobacterium adolescentis strain L2-32. *J. Biol Chem.* **294(32)**, 12040–12053 (2019).

10. Kallberg, Y., Oppermann, U., Jörnvall, H., & Persson, B. Short-chain dehydrogenases/reductases (SDRs). *Eur J Biochem.*, **269(18)**, 4409–4417 (2002).

11. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. *Endocr. Rev.*; **18 (9183566)**: 281-305 (1997).

12. Ridlon J.M., Ikegawa S., Alves J.M., Zhou B., Kobayashi A., Iida T., Mitamura K., Tanabe G., Serrano M., De Guzman A., Cooper P., Buck G.A., Hylemon P.B. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. *J. Lipid Res.* **54 (23772041)**: 2437-2449 (2013).

13. Kallberg, Y., Oppermann, U., Jörnvall, H., & Persson, B. Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes. *Protein Sci*, **11(3)**, 636-641 (2002).

14. Filling C., Berndt K.D., Benach J., Knapp S., Prozorovski T., Nordling E.,

Ladenstein R., Jörnvall H., Oppermann U. Critical residues for structure and

catalysis in short-chain dehydrogenases/reductases. *J. Biol. Chem.* **277**

(11976334): 25677-2568410.1074/jbc.M202160200, (2002)

15. Rossmann, M. G., Ford, G. C., Watson, H. C., & Banaszak, L. J. Molecular

symmetry of glyceraldehyde-3-phosphate dehydrogenase. *J Mol Biol.* **64(1)**,

237–245 (1972).

16. Thorn, A., Egerer-Sieber, C., Jäger, C. M., Herl, V., Müller-Uri, F., Kreis, W., &

Muller, Y. A. The crystal structure of progesterone 5β-reductase from Digitalis

lanata defines a novel class of short-chain dehydrogenases/reductases. *J Biol*

Chem., **283(25)**, 17260-17269 (2008).

17. Chen, M., & Penning, T. M. 5β-Reduced steroids and human Δ4-3-ketosteroid

5β-reductase (AKR1D1). *Steroids*, **83**, 17-26 (2014).

18. Le, H.H., Lee, MT., Besler, K.R. et al. Characterization of interactions of dietary

cholesterol with the murine and human gut microbiome. *Nat Microbiol.* **7**, 1390–

1403 (2022).

19. Li, C., Stražar, M., Mohamed, A.M.T., Pacheco, J. A., Walker, R. L., … & Xavier,

R. J. Gut microbiome and metabolome profiling in Framingham heart study

reveals cholesterol-metabolizing bacteria. *Cell*, **187**, 1-19. (2024).

20. Rosenfeld, R., Fukushima, D. K., Hellman, L., & Gallagher, T. F. The

transformation of cholesterol to coprostanol. *J Biol Chem*, **211(1)**, 301-311

(1954).

21. Björkhem, I., & Gustafsson, J. A. Mechanism of microbial transformation of

cholesterol into coprostanol. *Eur J Biochem.,* **21(3)**, 428–432 (1971).

22. Harrison, V. C., & Peat, G. Serum cholesterol and bowel flora in the newborn.

Am. J. Clin. Nutr., **28(12)**, 1351-1355 (1975).

23. Marshall, V. M., & Taylor, E. Ability of neonatal human Lactobacillus isolates to

remove cholesterol from liquid media. *Int. J. Food Sci. Technol.*, **30(5)**, 571-577

(1995).

24. Lye, H. S., Rusul, G., & Liong, M. T. Removal of cholesterol by lactobacilli via

incorporation and conversion to coprostanol. *J. Dairy Sci.*, **93(4)**, 1383-1392

(2010).

25. Fuentes, M. C., Lajo, T., Carrión, J. M., & Cuné, J. Cholesterol-lowering efficacy

of Lactobacillus plantarum CECT 7527, 7528 and 7529 in

hypercholesterolaemic adults. *Br. J. Nutr.*, **109(10)**, 1866-1872 (2013).

26. Costabile, A., Buttarazzi, I., Kolida, S., Quercia, S., Baldini, J., Swann, J. R., ...

& Gibson, G. R. An in vivo assessment of the cholesterol-lowering efficacy of

Lactobacillus plantarum ECGC 13110402 in normal to mildly

hypercholesterolaemic adults. *PLoS One*, **12(12)**, e0187964 (2017).

27. Tjandrawinata, R. R., Kartawijaya, M., & Hartanti, A. W. In vitro evaluation of

the anti-hypercholesterolemic effect of Lactobacillus Isolates from various

sources. *Front. Microbiol.*, **13**, 825251 (2022).

28. Cunningham, M., Azcarate-Peril, M. A., Barnard, A., Benoit, V., Grimaldi, R.,

Guyonnet, D., ... & Gibson, G. R. Shaping the future of probiotics and prebiotics.

Trends Microbiol., **29(8)**, 667-685 (2021).

29. Jörnvall, H., Persson, B., Krook, M., Atrian, S., Gonzalez-Duarte, R., Jeffery, J.,

& Ghosh, D. Short-chain dehydrogenases/reductases (SDR). *Biochemistry*,

34(18), 6003-6013 (1995).

30. Walter, J. Ecological role of lactobacilli in the gastrointestinal tract: implications

for fundamental and biomedical research. *Appl. Environ. Microbiol.*, **74(16)**,

4985-4996 (2008).

31. Dang, D., Liu, X., Chen, H., Zhao, J., Chen, W., & Yang, B. In silico, in vitro and

in vivo safety assessment of three Limosilactobacillus mucosae strains for

probiotic candidates. *Food Biosci.*, **57**, 103462 (2024).

32. Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E. H.,

... & Baigent, C. The effects of lowering LDL cholesterol with statin therapy in

people at low risk of vascular disease: a meta-analysis of individual data from

27 randomised trials. *Lancet*, **380(9841)**, 581-590 (2012).

33. Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., & Harats, D. Triglycerides and HDL

cholesterol: stars or second leads in diabetes? *Diabetes Care*, **32(Suppl 2)**,

S373 (2009).

34. Fernandez, M. L., & Andersen, C. J. Effects of dietary cholesterol in diabetes

and cardiovascular disease. *Clin Lipidol*, **9(6)**, 607-616 (2014).

35. https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-

risks/cholesterol-abnormalities--diabetes

36. Beniwal, A., Gaurav, A., Sharma, R., Ghosh, T., Kumar, P., Netter, U., ... &

Navani, N. K. Draft Genome Sequence of Limosilactobacillus fermentum Strain

NKN-51, Isolated from Fermented Yak Milk in the Western Himalayas of India.

Microbiol. Resour. Announc., **10(16)**, 10-1128 (2021).

37. Rudel, L. L., & Morris, M. D. Determination of cholesterol using o-

phthalaldehyde. *J. Lipid Res.*, **14(3)**, 364-366 (1973).

38. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., ...

& Hassabis, D. Highly accurate protein structure prediction with AlphaFold.

Nature, **596(7873)**, 583-589 (2021).

39. Mirdita, M., Schütze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., & Steinegger,

M. ColabFold: making protein folding accessible to all. *Nat. Methods*, **19(6)**,

679-682 (2022).

40. Steinegger, M., & Söding, J. MMseqs2 enables sensitive protein sequence

searching for the analysis of massive data sets. *Nat. Biotechnol.*, **35(11)**, 1026-

1028 (2017).

41. Schrödinger, L., & DeLano, W. (2020). *PyMOL*. Retrieved from

http://www.pymol.org/pymol

42. Holm, L., & Rosenström, P. Dali server: conservation mapping in 3D. *Nucleic*

Acids Res., **38**(Web Server issue), W545–W549 (2010).

43. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell,

D. S., & Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with

selective receptor flexibility. *J. Comput. Chem.*, **30(16)**, 2785-2791 (2009).

44. Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. AutoDock Vina 1.2.

0: New docking methods, expanded force field, and python bindings. *J Chem*

Inf Model., **61(8)**, 3891-3898 (2021).

45. UniProt Consortium. UniProt: a hub for protein information. *Nucleic Acids Res.*,

43(D1), D204-D212 (2015).

46. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and

high throughput. *Nucleic Acids Res*., **32**, 1792–1797 (2004).

47. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-

analysis of large phylogenies. *Bioinformatics*, **30(9)**, 1312-1313 (2014).

48. Gerlt, J. A., Bouvier, J. T., Davidson, D. B., Imker, H. J., Sadkhin, B., Slater, D. R., & Whalen, K. L. Enzyme function initiative-enzyme similarity tool (EFI-EST): a web tool for generating protein sequence similarity networks. *Biochim Biophys Acta.*, **1854(8)**, 1019-1037 (2015).

49. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., ... & Ideker, T. Cytoscape: a software environment for integrated models. *Genome Res.*, **13(22)**, 426 (1971).

50. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* **486**: 207–214, 2012. doi:10.1038/nature11234.

51. Methé, B. A., Nelson, K. E., Pop, M., Creasy, H. H., Giglio, M. G., Huttenhower, C., ... & Mannon, P. J. A framework for human microbiome research. *Nature*, **486(7402)**, 215 (2012).

52. Jonas Coelho Kasmanas, Alexander Bartholomäus, Felipe Borim Corrêa, Tamara Tal, Nico Jehmlich, Gunda Herberth, Martin von Bergen, Peter F Stadler, André Carlos Ponce de Leon Ferreira de Carvalho, Ulisses Nunes da Rocha, HumanMetagenomeDB: a public repository of curated and standardized metadata for human metagenomes, *Nucleic Acids Res.*, Volume 49, Issue D1, 8 January 2021, Pages D743–D750

53. Kaminski, J., Gibson, M. K., Franzosa, E. A., Segata, N., Dantas, G., & Huttenhower, C. High-specificity targeted functional profiling in microbial communities with ShortBRED. *PLoS Comput. Biol.*, **11(12)**, e1004557 (2015).

54. Zallot, R., Oberg, N., & Gerlt, J. A. The EFI web resource for genomic enzymology tools: leveraging protein, genome, and metagenome databases to

discover novel enzymes and metabolic pathways. *Biochemistry*, **58(41)**, 4169-4182 (2019).

55. Oberg, N., Zallot, R., & Gerlt, J. A. EFI-EST, EFI-GNT, and EFI-CGFP: enzyme function initiative (EFI) web resource for genomic enzymology tools. *J. Mol. Biol.*, **435(14)**, 168018 (2023).

56. Levin, B. J., Huang, Y. Y., Peck, S. C., Wei, Y., Martinez-Del Campo, A., Marks, J. A., ... & Balskus, E. P. A prominent glycyl radical enzyme in human gut microbiomes metabolizes trans-4-hydroxy-l-proline. *Science*, **355(6325)**, eaai8386 (2017).

57. Jia, B., Park, D., Hahn, Y., & Jeon, C. O. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. *Gut Microbes*, **11(5)**, 1300-1313 (2020).

58. Ewels, P., Magnusson, M., Lundin, S., & Käller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics*, **32(19)**, 3047-3048 (2016).

59. Li, D., Liu, C. M., Luo, R., Sadakane, K., & Lam, T. W. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics*, **31(10)**, 1674-1676 (2015).

60. Buchfink, B., Xie, C., & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. *Nat. Methods*, **12(1)**, 59-60 (2015).

Acknowledgments

Urmila Netter thanks the Council of Scientific and Industrial Research (CSIR), India, for providing a research fellowship. Vishakha Bisht and Amit Gaurav thank the Ministry of Human Resource and Development and the Department of Biotechnology (DBT)

782   Govt. of India for the financial support. We thank the Department of Biotechnology

783   (DBT), Govt. of India, for providing the funding to carry out the research work.

Contributions

U.N. designed, data curation, methodology, conceptualization of the project, and

writing the original draft. V.B. methodology and writing. A.G. Methodology, Data

curation, visualization, and writing. R.S. methodology. A.G. methodology. V.S.B.

methodology and data curation. KA. Formal analysis. K.T. Formal analysis and writing.

NKN Formal analysis, conceptualization, writing, resources, and project

administration.

Ethics declarations

Competing interests

The authors declare no competing interests.